好护士Herbapex品牌怎么样 申请店铺

我要投票 好护士Herbapex在鹿胎膏行业中的票数:718 更新时间:2026-01-28
好护士Herbapex是哪个国家的品牌?「好护士Herbapex」是辽宁上药好护士药业(集团)有限公司旗下著名品牌。该品牌发源于辽宁,由创始人左敏在2004-03-19期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力好护士Herbapex品牌出海!将品牌入驻外推网,定制好护士Herbapex品牌推广信息,可以显著提高好护士Herbapex产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

好护士Herbapex怎么样

辽宁好护士药业(集团)有限责任公司坐落于世界文化遗产——五女山山城脚下、辽宁省最大的湖泊——桓龙湖畔,1999年12月公司成立,2004年3月与上海实业集团合资,成为中外合资企业,先后通过GMP、ISO9001、ISO14000等多项认证。

目前集团公司可生产3个剂型,42个品种,其中国家中药保护品种15个,国家基本药物26个,独家生产品种7个,国家医保目录品种19个,基本上形成了以乳癖消为代表的乳系列产品,以尫痹片为代表的痹症系列产品,以强肾片为代表的肾系列产品,以益心宁神片为代表的心脑血管系列产品的产品结构群。主导品种乳癖消片作为问世二十多年的老品种,数十年畅销不衰,并成为治疗妇女乳腺病的首选药物,单品种年销售额超亿元,出口到俄罗斯、哈萨克斯坦、乌克兰、东南亚等地区和国家,在俄罗斯获得“梅奇尼克夫”金奖和“巩固民族健康贡献奖”,为中药在国际市场赢得了荣誉;痹症系列药是治疗风湿病、类风湿病的纯中药制剂,由中华中医药学会风湿病分会焦树德教授经十多年临床研究而开发的独家生产品种,采用辩证施治的原则,对症下药,因其纯中药制剂的特点,对患者无毒副反应,因而广受欢迎。

公司拥有现代化的生产厂房和设备,并采用国内最先进的生产技术,生产管理团队拥有执业药师、工程师等多名专业人才,同时又具有丰富的现场管理经验,生产队伍技术熟练,经验丰富。提取车间年处理药材量5000吨,是国家中药现代化示范工程,总投资3500万,建筑面积4500平方米,该车间采用大孔树脂吸附的先进提取技术,装配全自动化控制系统,实现生产全过程的自动化控制。固体制剂车间总投资2900万,建筑面积4100平方米,年产片剂40亿片,胶囊剂5亿粒,引进高速压片机、高效包衣机、全自动包装线等一系列先进设备,提高生产自动化水平。公司的提取技术和制剂水平在国内同行业处于一流水平。

公司技术研发中心为省级技术研发中心、辽宁省工程技术研究中心、本溪市重点实验室、中国医科大学生物制药研究所研发基地、辽宁中医学院实训基地,配备有国内一流的检测、检验、中试设备和专业的技术研发队伍。该中心在注重新产品开发步入生产、储备、研制的同时,一项重要的任务就是对在产品的生产工艺、设备进行研究,以提高生产技术水平。

公司营销网络覆盖全国(除台湾、西藏),现有营销人员近400人,设有特区办事处3个,大区办事处16个。通过专业推广、学术会议等多种形式提高公司和产品的形象和知名度,公司销售额连年创新高。

09年,公司“苍松”商标被评为全国驰名保护,“好护士”商标被评为辽宁省著名商标,这既是对公司以往业绩和知名度的认可,也是公司再上新台阶的一个新起点。“全国企业文化创新单位”、“辽宁省腾龙企业”、“辽宁省用户满意企业”、“辽宁省高新技术企业”、“中国质量万里行辽宁省示范单位”、“辽宁省农业产业化重点龙头企业”、“辽宁省创驰名保护先锋企业”等荣誉称号和资格认证见证了好护士药业曾经的辉煌业绩。以“做好人,做好药”为价值观的好护士药业,在发展中践行着“托起生命的太阳,呵护人类的健康”的企业宗旨,立志成为维护人类生命健康的“好护士”。

Liaoning good nurse Pharmaceutical (Group) Co., Ltd. is located at the foot of wunushan mountain city, the world cultural heritage, and Huanlong lake, the largest lake in Liaoning Province. The company was founded in December 1999. In March 2004, it became a Sino foreign joint venture with Shanghai industrial group. It has passed GMP, ISO9001, ISO14000 and other certifications. At present, the group company can produce 3 dosage forms, 42 varieties, including 15 national traditional Chinese medicine protection varieties, 26 national essential drugs, 7 exclusive production varieties, 19 national medical insurance catalogue varieties, basically forming a series of dairy products represented by Rupixiao, a series of Bi syndrome products represented by Jabi tablet, a series of kidney products represented by Qiangshen tablet, and a series of yixinningshen tablet The product structure group of cardiovascular and cerebrovascular products. The leading product Rupixiao tablet, as an old one that has been published for more than 20 years, has been selling well for decades, and has become the first choice drug for the treatment of women's breast disease. The annual sales of a single product has exceeded 100 million yuan, and it has been exported to Russia, Kazakhstan, Ukraine, Southeast Asia and other regions and countries. In Russia, it has won the gold medal of "Mechnikov" and the award of "contribution to the consolidation of national health", and it is a Chinese medicine in China The international market has won the honor; arthralgia series medicine is a pure Chinese medicine preparation for treating rheumatism and rheumatoid diseases. Professor Jiao Shude, the rheumatic branch of the Chinese society of traditional Chinese medicine, has developed an exclusive production variety after more than ten years of clinical research. It is based on the principle of dialectical treatment. It is widely welcomed because of the characteristics of its pure Chinese medicine preparation and its non-toxic side effects on patients. The company has modern production plant and equipment, and adopts the most advanced production technology in China. The production management team has many professional talents such as licensed pharmacists and engineers, as well as rich on-site management experience. The production team is skilled and experienced. The annual processing capacity of the extraction workshop is 5000 tons, which is a national modernization demonstration project of traditional Chinese medicine, with a total investment of 35 million yuan and a building area of 4500 square meters. The workshop adopts the advanced extraction technology of macroporous resin adsorption, assembles the full automatic control system, and realizes the automatic control of the whole production process. The total investment of the solid preparation workshop is 29 million, with a construction area of 4100 square meters. The annual output of the workshop is 4 billion tablets and 500 million capsules. A series of advanced equipment such as high-speed tablet pressing machine, high-efficiency coating machine and automatic packaging line are introduced to improve the production automation level. The company's extraction technology and preparation level are in the first-class level in the same industry in China. The company's technology R & D center is a provincial technology R & D center, Liaoning Engineering Technology Research Center, Benxi Key Laboratory, research and development base of Institute of Biopharmaceutics, China Medical University, and practical training base of Liaoning College of traditional Chinese medicine, equipped with domestic first-class testing, testing, pilot equipment and professional technology R & D team. While the center is focusing on the development of new products into production, storage and development, an important task is to study the production process and equipment of products in process, so as to improve the production technology level. The company's marketing network covers the whole country (except Taiwan and Tibet), with nearly 400 marketing personnel, 3 special zone offices and 16 regional offices. Through professional promotion, academic conferences and other forms to improve the image and popularity of the company and its products, the company's sales volume has reached a new high year after year. In 2009, the company's "Cangsong" trademark was awarded the national well-known protection, "good nurse" trademark was awarded the famous trademark of Liaoning Province, which is not only the recognition of the company's past performance and popularity, but also a new starting point for the company to go to a new level. "National enterprise culture innovation unit", "Liaoning Tenglong enterprise", "Liaoning user satisfaction Enterprise", "Liaoning high tech enterprise", "Liaoning demonstration unit of China's quality wanlihang", "key leading enterprise of agricultural industrialization in Liaoning Province", "Liaoning well-known protection pioneer enterprise" and other honorary titles and qualification certification have witnessed the past Brilliant achievements. The good nurse pharmaceutical industry, with the value of "be a good person, do a good job in medicine", practices the enterprise tenet of "holding up the sun of life, caring for human health" in the development, and is determined to become a "good nurse" to maintain human life and health.

本文链接: https://brand.waitui.com/bd64c2ad9.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

报告:2022年以来欧洲化工厂关闭率飙升,投资骤降、累计产能损失3700万吨

欧洲化工工业理事会(Cefic)1月28日发布报告显示,2022年以来,欧洲化工厂关闭率激增六倍,累计产能损失3700万吨,约占欧洲总产能的9%,导致化工行业直接失业2万人。与此同时,新增投资增速大幅放缓。确认投资产能从2022年的270万吨骤降至2025年的30万吨,2022年至2025年期间的这一数字约为700万吨。(界面)

32分钟前

Kimi K2.5发布24小时登顶全球开源榜单

36氪获悉,月之暗面Kimi 27日发布的K2.5模型在上线一天后已登顶全球多个榜单。在权威榜单LMarena上,Kimi K2.5中仅次Claude opus 4.5、Genimi3 Pro等闭源模型,位居开源榜首。在著名独立评测机构Artificial Analysis的榜单中,Kimi K2.5位列第5,也在所有开源模型中排名最高。

32分钟前

麦格米特:2025年净利同比预降65.61%-72.48%

36氪获悉,麦格米特公告,预计2025年归属于上市公司股东的净利润为1.20亿元-1.50亿元,比上年同期下降65.61%-72.48%。业绩变动主要系公司持续加大AI电源等新兴领域研发投入及海外、杭州基地建设导致管理费用增加,叠加部分行业成本压力致毛利率下滑,以及汇率波动引发较大汇兑损失。

32分钟前

北方股份:连续3日股价涨幅偏离值累计超20%,提示交易风险

36氪获悉,北方股份公告,公司股票于2026年1月26 - 28日连续3个交易日内收盘价格涨幅偏离值累计超20%,属异常波动。经自查,公司生产经营正常,无重大调整;公司、控股股东及实控人无应披露未披露重大信息,未发现需澄清的报道或传闻,不涉及热点概念。异常波动期间,董高监、控股股东及实控人无买卖公司股票情况。公司提醒投资者注意交易风险,以指定媒体披露信息为准。

32分钟前

*ST仁东:核心子公司合利宝支付牌照处于中止审查阶段,正积极推动换牌续展工作

36氪获悉,*ST仁东公告,公司股票交易价格连续3个交易日(2026年1月26日、2026年1月27日、2026年1月28日)收盘价格涨幅偏离值累计超过12%,属于股票交易异常波动情形。公司当前主营业务为第三方支付,核心子公司广州合利宝支付科技有限公司(简称“合利宝”)作为持牌主体,其支付牌照处于中止审查阶段,目前合利宝正与监管部门保持密切沟通,正积极推动换牌续展工作。但支付业务许可证续展进度受到行业监管政策和主管机关审批影响,存在因政策性因素或自身相关因素导致的续展进度不及预期的风险。

32分钟前

本页详细列出关于好护士Herbapex的品牌信息,含品牌所属公司介绍,好护士Herbapex所处行业的品牌地位及优势。
咨询